Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Corvus Pharmaceuticals, Inc. (CRVS) had Consolidated Net Income/Loss of $15.19M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$15.19M |
|
-- |
|
-- |
|
$9.92M |
|
$-9.92M |
|
$25.11M |
|
$15.19M |
|
$15.19M |
|
$15.19M |
|
$15.19M |
|
|
Consolidated Net Income/Loss |
$15.19M |
$15.19M |
|
$-9.92M |
|
$-10.19M |
|
72.13M |
|
75.15M |
|
$0.21 |
|
$-0.13 |
|
| Balance Sheet Financials | |
$45.49M |
|
$0.17M |
|
$13.95M |
|
$59.44M |
|
$9.28M |
|
-- |
|
$0.83M |
|
$10.11M |
|
$49.33M |
|
$49.33M |
|
$49.33M |
|
68.17M |
|
| Cash Flow Statement Financials | |
$-8.26M |
|
$4.24M |
|
$0.28M |
|
$8.74M |
|
$5.00M |
|
$-3.74M |
|
$1.25M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.90 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-8.30M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
30.80% |
|
30.80% |
|
25.56% |
|
30.80% |
|
$0.72 |
|
$-0.11 |
|
$-0.11 |
|